Sweden's Devyser Q4 sales rise 12.1% yr/yr

Devyser Diagnostics AB

12/02/2026 06:38

Overview

Genetic testing solutions provider's Q4 net sales rose 12.1% yr/yr

Operating profit for Q4 reached SEK 18.0 mln, marking positive earnings trend

Company announced acquisition of Cybergene AB

Outlook

Company did not provide specific guidance for future quarters or full year 2026

Result Drivers

COST DISCIPLINE - Devyser attributed its positive operating profit to cost discipline and strategic priorities, per CEO Jan Wahlström

SALES GROWTH - Net sales increased by 12.1% yr/yr, with a 20.9% increase when adjusted for exchange rate fluctuations

REGULATORY APPROVALS - IVDR approval of Devyser CFTR and Health Canada approval for chimerism test supported regulatory compliance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 72 mln
Q4 Adjusted EPS
SEK 0.82
Q4 Net Income
SEK 13.60 mln
Q4 Adjusted Free Cash Flow
SEK 11.70 mln
Q4 EBIT
SEK 18 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Devyser Diagnostics AB is SEK160.00, about 57.2% above its February 11 closing price of SEK101.80

The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 52 three months ago

Press Release: ID:nMFN5C9HQg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)